Abstracts tagged "Disease-modifying antirheumatic drugs"

Abstract Number: 1336 • 2019 ACR/ARP Annual Meeting
Systematic Literature Review and Meta-Analysis of DAS28 Clinical Response Rates Among Advanced Therapies in Biologic-Naïve Patients with Rheumatoid Arthritis
Daniel Aletaha¹, Ruta Sawant ², Patrick Zueger ³, Erin Cook ⁴, Fan Mu ⁴, Vishvas Garg ² and Keith A. Betts ⁴, ¹Medical University of Vienna, Vienna, Austria, ²AbbVie Inc., North Chicago, IL, ³AbbVie Inc., North Chicago, ⁴Analysis Group, Inc., Boston, MA
Background/Purpose: Biologic (b) and targeted synthetic (ts) DMARDs have demonstrated efficacy for the treatment of rheumatoid arthritis (RA) in clinical trials; however, real-world evidence on…
Abstract Number: 1343 • 2019 ACR/ARP Annual Meeting
Pop a Pill or Give Myself a Shot? Patient Perspectives of Disease-modifying Anti-rheumatic Drug (DMARD) Choice for Rheumatoid Arthritis (RA)
Jasvinder Singh¹, Haley Tornberg ² and Susan Goodman ³, ¹University of Alabama Medical Center, Birmingham, ²Hospital for Special Surgery, New York, NY, ³Hospital For Special Surgery/Weill Cornell Medicine, New York, NY
Background/Purpose: Little is known about the patient perspective related to DMARD choice in RA. Our objective was to assess how patients decide whether to add…
Abstract Number: 1393 • 2019 ACR/ARP Annual Meeting
Impact of Sarilumab on Unacceptable Pain and Inflammation Control in Moderately-to-Severely Active Rheumatoid Arthritis (RA) Patients in 3 Phase 3 Studies
Vivian Bykerk¹, Wenhui Wei ², Susan Boklage ², Toshio Kimura ², Stefano Fiore ³ and Gregory St John ⁴, ¹Hospital for Special Surgery, New York City, NY, ²Regeneron Pharmaceuticals, Inc, Tarrytown, NY, ³Sanofi Genzyme, Bridgewater, NJ, ⁴Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Background/Purpose: Pain, a core-set domain and a troubling symptom to patients with RA, may be directly related to inflammation. Unacceptable pain (UP) levels may persist…
Abstract Number: 1414 • 2019 ACR/ARP Annual Meeting
Improvement of Mental Health and Quality of Life During Therapy with Tocilizumab
Frank Behrens¹, Werner A Biewer ², Gerd Burmester ³, Martin Feuchtenberger ⁴, Michael W. Hofmann ⁵, Peter Kästner ⁶, Herbert Kellner ⁷, Ramona König ⁸, Anke Liebhaber ⁹, Christina Luig ¹⁰, Regina Max ¹¹, Patrizia Sternad ¹², Hans-Peter Tony ¹³ and Christopher Amberger ¹⁴, ¹Rheumatology Goethe-University Frankfurt & Fraunhofer IME-TMP, Frankfurt, Germany, ²Rheumatologische Schwerpunktpraxis Saarbrücken, Saarbrücken, Germany, ³Charité—University Medicine Berlin, Berlin, Germany, ⁴Rheumatologie/Klinische Immunologie, Kreiskliniken Altötting-Burghausen, Burghausen, Germany, ⁵Chugai Pharma Europe Ltd., Frankfurt/Main, Germany, ⁶MVZ Ambulantes Rheumazentrum Erfurt, Erfurt, Germany, ⁷Praxis Prof. Herbert Kellner, Munich, Germany, ⁸Justus-Liebig-Universität Giessen and Kerckhoff-Klinik-Forschungs-GmbH, Giessen, Germany, ⁹Internistisch-Rheumatologische Arztpraxis, Halle, Halle, Germany, ¹⁰Roche Pharma AG, Rheumatologie, Grenzach-Wyhlen, Germany, ¹¹Universitätsklinikum Heidelberg, Heidelberg, Germany, ¹²Gemeinschaftspraxis, Planegg, Planegg, Germany, ¹³Department of Rheumatology/Clinical Immunology, University Hospital, Wuerzburg, Germany, Würzburg, Germany, ¹⁴Rheumatologische Gemeinschaftspraxis Dr. Pick/Dr. Amberger, Bad Neuenahr, Germany
Background/Purpose: In rheumatoid arthritis (RA), the proinflammatory cytokine IL-6 is associated with mental disorders such as depression and anxiety.1 Furthermore, depression and anxiety are comorbidities…
Abstract Number: 2370 • 2019 ACR/ARP Annual Meeting
Discontinuation of Disease Modifying Drugs in Patients with Incident Rheumatoid Arthritis
pia Lois¹, Zulema Rosales Rosado ¹, Judit Font Urgelles ², Cristina Vadillo Font ¹, isabel Hernandez Rodriguez ¹, Juan Angel Jover Jover ¹ and lydia Abasolo Alcazar ¹, ¹HOSPITAL CLINICO SAN CARLOS, MADRID, Spain, ²HOSPITAL CLINICO SAN CARLOS, MADRID, Madrid, Spain
Background/Purpose: Treatment of Rheumatoid Arthritis (RA) has undergone a big change in the last two decades in strategies, objectives and therapeutic options, especially with the…
Abstract Number: 2387 • 2019 ACR/ARP Annual Meeting
Management of Patients with Incident Rheumatoid Arthritis in Rheumatology Clinical Practice
isabel Hernandez Rodriguez¹, Zulema Rosales Rosado ¹, pia Lois ¹, Cristina Lajas ¹, Judit Font Urgelles ², Juan Angel Jover Jover ¹ and lydia Abasolo Alcazar ¹, ¹HOSPITAL CLINICO SAN CARLOS, MADRID, Spain, ²HOSPITAL CLINICO SAN CARLOS, MADRID, Madrid, Spain
Background/Purpose: Treatment of Rheumatoid Arthritis (RA) has changed drastically in the last two decades in strategies and objectives, as well as in therapeutic options, especially…
Abstract Number: 2833 • 2019 ACR/ARP Annual Meeting
Shared Decision Making in Routine Clinical Practice: An Assessment of Audio-recorded Consultations with Rheumatoid Arthritis Patients
Elke Mathijssen¹, Johanna Vriezekolk ² and Bart van den Bemt ², ¹Sint Maartenskliniek, Ubbergen, Netherlands, ²Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: International guidelines for rheumatoid arthritis (RA) treatment emphasize that all treatment decisions should be made through a shared decision making (SDM) process between clinicians…
Abstract Number: 507 • 2019 ACR/ARP Annual Meeting
Inhibition of Joint Destruction in Patients with Rheumatoid Arthritis Treated with Peficitinib in Combination with Methotrexate: A Randomized, Double-Blind, Placebo-Controlled Trial in Japan
Tsutomu Takeuchi¹, Yoshiya Tanaka ², Mitsuhiro Rokuda ³, Hiroyuki Izutsu ³, Yuichiro Kaneko ³, Musashi Fukuda ³, Daisuke Kato ³ and Désirée van der Heijde ⁴, ¹Keio University School of Medicine, Tokyo, Japan, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³Astellas Pharma, Inc., Tokyo, Japan, ⁴Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Peficitinib (PEF), a novel oral Janus kinase (JAK) inhibitor, has demonstrated efficacy in Phase 3 studies of patients with RA (NCT02305849).1 We report the…
Abstract Number: 519 • 2019 ACR/ARP Annual Meeting
Efficacy of Biosimilar Candidate ABP 710 in a Phase 3 Study in Subjects with Moderate to Severe RA: Additional Analysis Focusing on the ACR Individual Components
Mark Genovese¹, Juan Sanchez-Burson ², Éva Balázs ³, Andrea Everding ⁴, MyungShin Oh ⁵, Gary Fanjiang ⁵ and Stanley Cohen ⁶, ¹Stanford University, Stanford, CA, ²Hospital Infanta Luisa, Sevilla, Spain, ³Dr. Bugyi István Hospital, Szentes, Hungary, ⁴HRF Hamburger Rheuma Forschungszentrum, Hamburg, Germany, ⁵Amgen, Thousand Oaks, CA, ⁶Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: ABP 710 is being developed as a biosimilar to infliximab. Both ABP 710 and infliximab reference product (RP) inhibit tumor necrosis factor-alpha. Following demonstration…
Abstract Number: 520 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety Results from a Phase 3 Study of Biosimilar Candidate ABP 710 in Subjects with Moderate to Severe RA
Mark Genovese¹, Juan Sanchez-Burson ², Éva Balázs ³, Andrea Everding ⁴, MyungShin Oh ⁵, Gary Fanjiang ⁵ and Stanley Cohen ⁶, ¹Stanford University, Stanford, CA, ²Hospital Infanta Luisa, Sevilla, Spain, ³Dr. Bugyi István Hospital, Szentes, Hungary, ⁴HRF Hamburger Rheuma Forschungszentrum, Hamburg, Germany, ⁵Amgen, Thousand Oaks, CA, ⁶Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: ABP 710 is being developed as a biosimilar to infliximab. Both ABP 710 and infliximab reference product (RP) inhibit tumor necrosis factor-alpha and have…
Abstract Number: 521 • 2019 ACR/ARP Annual Meeting
Discontinuation of Disease Modifying Drugs Due to Inefficacy in Patients with Incident Rheumatoid Arthritis
Zulema Rosales Rosado¹, pia Lois ¹, Arkaitz Mucientes Ruiz ¹, Esperanza Pato Cour ¹, Dalifer Freites Nuñez ², Juan Angel Jover Jover ¹, lydia Abasolo Alcazar ¹ and Leticia León ³, ¹HOSPITAL CLINICO SAN CARLOS, MADRID, Spain, ²Hospital Clínico San Carlos, MADRID, Spain, ³Fundación para la Investigación Biomedica, Madrid, Madrid, Spain
Background/Purpose: The treatment of Rheumatoid Arthritis (RA) has undergone a big change in the last two decades with the Disease Modifying Drugs (DMARDs). These drugs…
Abstract Number: 528 • 2019 ACR/ARP Annual Meeting
Assessment of Bone and Cartilage Turnover Markers Following Treatment with Repository Corticotropin Injection in Patients with Persistently Active Rheumatoid Arthritis
Roy Fleischmann¹, Daniel Furst ², Erin Connolly-Strong ³, Jingyu Liu ³, Julie Zhu ³ and Richard Brasington ⁴, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²University of California, Los Angeles, CA, ³Mallinckrodt Pharmaceuticals, ARD, LLC, Bedminster, NJ, ⁴Washington University School of Medicine in St Louis, St Louis, MO
Background/Purpose: Persistently active rheumatoid arthritis (RA) is an autoimmune disorder characterized by chronic inflammation and bone loss.1 Although short-term administration of corticosteroids (CSs) is recommended…
Abstract Number: 849 • 2019 ACR/ARP Annual Meeting
Risk of Malignancies Associated with Biologics in Rheumatoid Arthritis: Analysis of a National Claim Database
Raphaèle Seror¹, Alexandre Lafourcade ², yann De Rycke ², Bruno Fautrel ³, Xavier Mariette ⁴ and Florence Tubach ⁵, ¹Université Paris Sud, Hôpitaux Universitaires Paris-Sud, AP-HP, INSERM UMR 1184, Le Kremlin-Bicêtre, France, ²Biostatistics, Public Health and Medical Information department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France, Paris, France, ³Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France, ⁴Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, ⁵Pitié Salpétrière University-Hospital, Paris, Ile-de-France, France
Background/Purpose: Our objectives were to estimate and compare the incidence rate of malignancies between biologic and csDMARD-treated RA patients.Methods: We conducted an historical cohort study…
Abstract Number: 953 • 2019 ACR/ARP Annual Meeting
Treatment Patterns and Persistency Following the First Biologic DMARD in Patients with Rheumatoid Arthritis: Real-World Analysis of 2012–2016 US Medicare Data
Robin Dore¹, Lawrence Chang ², Yuanyuan Ji ³, Suying Li ³, Jenya Antonova ² and Mark Genovese ⁴, ¹Private practice, Tustin, CA, ²Gilead Sciences, Foster City, CA, ³Chronic Disease Research Group, Minneapolis, MN, ⁴Stanford University, Stanford, CA
Background/Purpose: In RA patients not meeting treat-to-target goals despite treatment with a biologic (b)DMARD, ACR guidelines1 recommend using other targeted immunomodulators (TIM): TNF-α inhibitor (TNFi),…
Abstract Number: 1134 • 2019 ACR/ARP Annual Meeting
Medicaid Spending (2013-2017) on Disease Modifying Agents Commonly Used in Rheumatoid Arthritis
Deepan Dalal¹, Tingting Zhang ² and Theresa Shireman ², ¹Brown University, Riverside, RI, ²Brown University, Providence, RI
Background/Purpose: The management of rheumatoid arthritis (RA) and other conditions have improved tremendously since the introduction of biologic disease modifying agents (DMARDs). However, these agents…

1
2
3
…
5
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].